ITEM 5.02: DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On January 21, 2021, Michael Sander notified the Board of Directors of Immune Therapeutics, Inc. (the "Company") of his resignation as a director of the Company, effective on January 21, 2021, to pursue other interests. Mr. Sander served as director from November 2019.

Board Chair Dr. Roscoe M. Moore, Jr. stated that "the Board and shareholders of Immune Therapeutics, Inc. wish to thank Michael for his dedicated service to the Company. During his tenure, Michael added strong insights and direction to the Company. We wish him well in his future endeavors".

Mr. Sander's resignation was not the result of any dispute or disagreement with the Company or the Company's Board of Directors on any matter relating to operations, policies or practices of the Company.

© Edgar Online, source Glimpses